Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Randomized Double-blind Placebo-controlled Two-way Cross-over Trial of the Effects of Repeat Doses of 50 mg AXP1275 Daily on the Asthmatic Response to a Pulmonary Allergen Challenge in Adults With Mild-to-Moderate Atopic Asthma

NCT01890161 is registered in ClinicalTrials.gov with Axikin Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01890161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01890161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Randomized Double-blind Placebo-controlled Two-way Cross-over Trial of the Effects of Repeat Doses of 50 mg AXP1275 Daily on the Asthmatic Response to a Pulmonary Allergen Challenge in Adults With Mild-to-Moderate Atopic Asthma
Lead sponsor
Axikin Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2013
Completion date
April 30, 2014
Enrollment
21 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

atopic asthma